Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026

Rhea-AI Summary

Spero Therapeutics (Nasdaq: SPRO) will report first quarter 2026 financial results for the period ended March 31, 2026, and provide a business update on May 13, 2026 after market close. The company announced it does not intend to host a conference call.

News Market Reaction – SPRO

+4.55%

+4.55% Session close to close

In the May 6 session, SPRO gained 4.55%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets expectations for Q1 2026 results on May 13, 2026 and notes that the company w...

Analysis

This announcement sets expectations for Q1 2026 results on May 13, 2026 and notes that the company will not host a conference call, consistent with the prior earnings date communication. Investors may contextualize the upcoming release against 2025 net income of $8.6M, reduced R&D spending, and the tebipenem HBr PDUFA date of June 18, 2026. Attention may focus on cash trends, collaboration revenue, and regulatory progress disclosures.

Key Figures

Earnings release date: May 13, 2026 Quarter end date: March 31, 2026

2 metrics

Earnings release date May 13, 2026 Q1 2026 financial results to be reported after market close

Quarter end date March 31, 2026 First quarter 2026 reporting period referenced in announcement

Previous Earnings date Reports

1 past event · Latest: Mar 18 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 18	Earnings date notice	Neutral	+0.4%	Set Q4 and full-year 2025 results date with no conference call planned.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Prior earnings date scheduling news led to a small positive price reaction.

Recent Company History

Recent updates emphasized tebipenem HBr, including NDA resubmission and an FDA PDUFA date of June 18, 2026, alongside a 2025 turnaround to net income and reduced R&D spend. A prior earnings date announcement on March 18, 2026 produced a modest 0.41% gain. Against this backdrop, the new Q1 2026 reporting date continues a pattern of providing timing updates without hosting conference calls.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced that it will report its financial results for the first quarter ended March 31, 2026, and provide a business update on Wednesday, May 13, 2026, after market close. The Company does not intend to host a conference call.

About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need. For more information, visit www.sperotherapeutics.com.

Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
IR@Sperotherapeutics.com

Media Inquiries: 
media@sperotherapeutics.com

FAQ

When will Spero Therapeutics (SPRO) report Q1 2026 results and provide a business update?

Spero Therapeutics will report Q1 2026 results and give a business update on May 13, 2026 after market close. According to the company, the update covers results for the quarter ended March 31, 2026 and related business matters.

Will Spero Therapeutics (SPRO) host a conference call for the May 13, 2026 business update?

No, Spero Therapeutics does not intend to host a conference call for the May 13, 2026 update. According to the company, results and the business update will be released after market close without a live call.

What period do the Spero Therapeutics (SPRO) Q1 2026 financial results cover?

The Q1 2026 financial results cover the quarter ended March 31, 2026. According to the company, the published results and business update will reflect financial and operational activity for that quarter.

How can investors access Spero Therapeutics (SPRO) Q1 2026 results on May 13, 2026?

Investors can access the Q1 2026 results when they are released after market close on May 13, 2026. According to the company, results and the business update will be available through its investor relations channels and public filings.

Does the May 13, 2026 Spero Therapeutics (SPRO) release include clinical updates?

The company said it will provide a business update on May 13, 2026, which may include clinical program information. According to the company, the update accompanies the Q1 2026 financial results released after market close.